Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell ...
On5, 2025, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or ...
Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight ...
Artios Pharma has successfully closed an oversubscribed $115million Series D financing round co-led by founding investor SV ...
Highlighting 10 innovative late-stage BioPharma drugs with the potential to reshape treatment paradigms and industry dynamics ...
Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or ...
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in the Phase I/II clinical trial of its ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data ...
Joshua Lederberg, Nobel laureate and president of Rockefeller University, is well known in biology circles. Not so his wife, ...
In a move that could significantly reshape India's pharmaceutical procurement landscape, the Department of Pharmaceuticals ...
DNA (deoxyribonucleic acid) is the nucleic acid polymer that forms the genetic code for a cell or virus. Most DNA molecules consist of two polymers (double-stranded) of four nucleotides that each ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback